Keros Therapeutics (KROS)
Develops protein therapeutics for neuromuscular disease and blood-cell disorders.
Something off on this page? Send us feedback.
Develops protein therapeutics tied to TGF-beta family signaling, with rinvatercept focused on Duchenne muscular dystrophy and ALS and elritercept advanced through Takeda and Hansoh collaborations. Revenue is collaboration-based rather than commercial product sales, and the business depends on clinical progress, partner execution, and regulatory engagement.
Develops clinical-stage protein therapeutics for diseases linked to dysfunctional TGF-beta family signaling. The current pipeline is centered on rinvatercept, the lead candidate for Duchenne muscular dystrophy and ALS, and elritercept, the most advanced candidate for cytopenias in myelodysplastic syndrome and myelofibrosis.
Operates from Lexington, Massachusetts with a single reportable segment and no commercial product sales identified in current filings. Revenue is tied to Takeda and Hansoh collaboration arrangements, with elritercept rights split by territory and rinvatercept retained as the strategic focus.
Execution now reflects a narrower, data-driven portfolio after cibotercept was discontinued and the company completed a restructuring. The business depends on clinical trial results, partner-led elritercept development, and regulatory paths for neuromuscular indications.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 4, 2026 | Wells Fargo | Reiterate | Rating: —Target: — | Target: $18 |
| Aug 4, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: — | Target: $20 |
| Aug 4, 2026 | Leerink Partners | Reiterate | Rating: —Target: — | Target: $23 |
| Jun 10, 2025 | B of A Securities | Downgrade | ||
| Jan 21, 2025 | Cantor Fitzgerald | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $257.6M · Total debt $15.7M · Total assets $287.6M · Shareholders' equity $262.3M
- Revenue
- $0
- Operating income
- −$30.9M
- Net income
- −$28.7M
No dividends on record.
| Institutions | 94.38% | 18.71M shares | |
|---|---|---|---|
| 134 holders · as of Jun 30, 2026 | |||
| Insiders | 9.35% | 1.85M shares | |
| 17 holders · as of Aug 20, 2026 | |||
| Strategic holders | 23.36% | 4.63M shares | |
| 1 holder · as of Oct 17, 2025 | |||
| Adds to | 127.09% | ||
19.83M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 127.09%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Pontifax Management 4 G.P. (2015) Ltd.1Strategic10 percent owner | 23.36% | 4.73M | filed Oct 17, 2025 |
BlackRock, Inc.Institution | 14.09% | 2.79M | as of Jun 30, 2026 |
Nantahala Capital Management, LLCInstitution | 7.11% | 1.41M | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 4.88% | 967,859 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.20% | 833,596 | as of Jun 30, 2026 |
- Pontifax Management 4 G.P. (2015) Ltd.'s transaction reports restate only vehicles that traded; the 2020 ownership statement (4.73M) less the 102.4K net shares sold since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Charles W. Newton | director | −551 | $10.30 |
| Aug 18, 2026 | Esther Cho | officer: Chief Legal Officer | −4,485 | $10.29 |
| Aug 18, 2026 | Lorena Raquel Lerner | officer: Chief Scientific Officer | −3,568 | $10.29 |
| Aug 18, 2026 | Annita Tanini | officer: Corp. Controller & VP, Finance | −1,224 | $10.29 |
| Aug 17, 2026 | Jean Jacques Bienaime | director | +1,000 | $10.27 |
- Bristol-Myers Squibb
Approved activin-ligand-trap anemia therapy in MDS and MF
- Sarepta Therapeutics
Commercial Duchenne portfolio and broad neuromuscular pipeline
- Edgewise Therapeutics
Late-stage muscle-damage program in DMD and Becker dystrophy
- GSK (ADR)
Approved MF-anemia therapy with JAK1/2 and ACVR1 activity
- Geron
Commercial LR-MDS anemia therapy and Phase 3 MF program
- Dyne Therapeutics
Exon-51 DMD program moving toward accelerated approval
- Scholar Rock
Myostatin platform spanning SMA and rare neuromuscular disease
- Biogen
Approved genetically targeted ALS therapy and confirmatory trial
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Keros Therapeutics | $11.60 | −1.11% | $232.6M | — | — | 15.5 | −99.8% |
| Bristol-Myers Squibb | $61.51 | −1.19% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| Sarepta Therapeutics | $19.15 | −7.98% | $2.20B | — | 33.3 | 1.1 | −34.3% |
| Edgewise Therapeutics | $40.54 | −8.92% | $4.79B | — | — | — | — |
| GSK (ADR) | $49.81 | −1.79% | $101.62B | 16.1 | 9.2 | 2.3 | +5.3% |
| Geron | $1.24 | −5.73% | $840.4M | — | 88.3 | 4.1 | +17.2% |
| Dyne Therapeutics | $16.33 | −4.75% | $3.20B | — | — | — | — |
| Scholar Rock | $50.37 | −1.60% | $6.13B | — | — | — | — |
| Biogen | $223.57 | −0.80% | $33.30B | 39.9 | 16.9 | 3.3 | +3.4% |
| Median | 16.1 | 16.9 | 2.6 | +5.3% |